

The Manager
Company Announcements Office
ASX Limited

LBT RAISES A\$1.5M IN PRIVATE PLACEMENT TO ADVANCE TECHNOLOGY COMMERCIALISATION

- *With SPP of up to \$1.5m fund raising targeting total of \$3m*

Adelaide 18 June 2014: LBT Innovations (ASX: LBT) has completed a placement of new shares to professional and sophisticated investors at 13.5 cents per share, providing additional capital of \$1.5 million. LBT also intends to offer a Share Purchase Plan (SPP) at 13.5 cents per share, capped at \$1.5 million, to shareholders registered at 7pm AEST on 13 June 2014, making a total fund raising of \$3 million.

LBT can now consolidate its development and commercialisation strategy including:

- Undertaking the APAS® clinical trial programme, proposing to conduct two trials in Australia and a third trial in the US, to support a 510K *de-novo* submission to US Food and Drug Administration (FDA);
- Progress the line extension products for APAS®; and
- Initiate the proof of concept study for the proposed new technology called Woundvue™.

LBT Chief Executive Officer Lusia Guthrie commented, "LBT's capital raising strengthens our position to take APAS® through to US FDA market pre-approval. We will also be able to initiate the development of Woundvue™, the next product in our Intelligent Imaging Platform. Our 50%-owned JV company Zurich-based Clever Culture Systems AG, is in discussions with major diagnostics companies about a global distribution deal for APAS."

The placement will comprise both an amount to be issued under the 15% placement capacity of the Company in accordance with ASX listing rule 7.1 and another amount subject to shareholder approval at an Extraordinary General Meeting on or around Wednesday 30 July 2014.

Bell Potter Securities Limited is Lead Manager and Bookrunner of the placement.

Offer Details:

The Placement comprises two Tranches:

- Tranche 1 is a \$0.4 million placement to professional and sophisticated investors using existing placement capacity under the ASX Listing Rules (First Tranche Placement)
- Tranche 2 is a \$1.1 million placement to professional and sophisticated investors and is subject to shareholder approval (Second Tranche Placement). A shareholder meeting is expected to be held on or around 30 July 2014.

The SPP will be offered to eligible shareholders on the record date at the Offer Price capped raising up to a maximum of A\$1.5 million. Eligible shareholders will be able to apply for up to A\$15,000 of new fully paid ordinary shares at the Offer Price.

Shares issued under the Placement and the Share Purchase Plan will rank equally with existing shares.

Forward Looking Statements:

This ASX announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of LBT to be materially different from the statements in this announcement:

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has 2 breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™ a proposed automation solution to assist in the management of chronic wounds.

LBT has a global, exclusive licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories in around the world. LBT's APAS® technology (Automated Plate Assessment System) is nearing market. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au